CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2018—Qiagen announced a collaboration with SRL, a large clinical testing laboratory company in Japan, to prepare for introducing new companion diagnostics simultaneously with new drug approvals. The nonexclusive master collaboration agreement for clinical laboratory research services will enable rapid implementation by SRL of Qiagen’s companion diagnostic workflows upon approval of the drugs and tests by Japan’s Pharmaceuticals and Medical Devices Agency.
Qiagen’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement, and alignment of medical communication by SRL, Qiagen, and pharmaceutical partners. The agreement will cover a range of Qiagen companion diagnostics, including real-time polymerase chain reaction and next-generation sequencing solutions. Initial projects involve Qiagen companion diagnostics paired with drugs under development in Japan for solid tumors and leukemia.